Infinity Pharma (INFI) Misses Q1 EPS by 23c

Infinity Pharma (NASDAQ: INFI) reported Q1 EPS of ($1.91), $0.23 worse than the analyst estimate of ($1.68). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.79 million.

For earnings history and earnings-related data on Infinity Pharma (INFI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery